Table 1 Description of the study population and characteristics of the exacerbation, according to the viral status at exacerbation and at steady state
All | V+ | V- | V + V+ | V + V- | V+ versus V- P value (ASD) | V + V+ versus V + V- P value (ASD) | |
|---|---|---|---|---|---|---|---|
Total (n) | 72 | 46 | 26 | 17 | 23 | ||
Median age (years) | 8.9 [6–15.3] | 9.2 [6–15] | 8.7 [6.2–15.3] | 8.4 [6–12] | 9.8 [6–14,3] | 0.35 (22.6) | 0.04 (71.9) |
Gender | |||||||
- Boys (n) | 52 | 31 | 21 | 13 | 15 | 0.22 | 0.44 |
- Girls (n) | 20 | 15 | 5 | 4 | 8 | (30.9) | (25.0) |
Frequent exacerbations (>2/y) (n) | 27 | 18 | 9 | 6 | 12 | 0.70 (9.4) | 0.29 (34.5) |
Maintenance treatment before inclusion (n) | 32 | 21 | 11 | ND | ND | 0.78 (6.7) | 0.96 (1.5) |
Atopic dermatitis (n) | 30 | 16 | 14 | 5 | 9 | 0.11 (39.1) | 0.51 (20.6) |
Allergic rhinitis (n) | 50 | 31 | 19 | 11 | 15 | 0.61 (12.5) | 0.97 (1.1) |
Food allergy (n) | 11 | 6 | 5 | 2 | 3 | 0. 51 (16.9) | 1 (3.9) |
Passive tobacco exposure (n) | 39 | 23 | 16 | 9 | 12 | 0.39 (21.1) | 0.96 (1.5) |